Table 5.
Prevalence of dyslipidaemia and its components according to the quartile of alcohol dietary pattern score in men (n 1354) and women
(Odds ratio and 95 % confidence intervals, n 817)
| Q1 | Q2 | Q3 | Q4 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | OR | 95 % CI | OR | 95 % CI | OR | 95 % CI | P for trend | ||
| Men | |||||||||
| n | 213 | 316 | 382 | 443 | |||||
| Dyslipidaemia | Number of cases | 106 | 152 | 201 | 236 | ||||
| Number of cases (per 1000 person) | 498 | 481 | 526 | 533 | |||||
| Model 1* | 1·00 (reference) | 0·98 | 0·69, 1·4 | 1·18 | 0·83, 1·66 | 1·15 | 0·82, 1·61 | 0·26 | |
| Model 2† | 1·00 (reference) | 1·02 | 0·7, 1·47 | 1·18 | 0·83, 1·68 | 1·09 | 0·76, 1·55 | 0·52 | |
| Model 3‡ | 1·00 (reference) | 1·02 | 0·71, 1·48 | 1·20 | 0·83, 1·72 | 1·13 | 0·75, 1·69 | 0·42 | |
| High LDL-cholesterol | Number of cases | 89 | 131 | 157 | 154 | ||||
| Number of cases (per 1000 person) | 418 | 415 | 411 | 348 | |||||
| Model 1* | 1·00 (reference) | 1·02 | 0·71, 1·46 | 1·01 | 0·71, 1·43 | 0·75 | 0·53, 1·06 | 0·06 | |
| Model 2† | 1·00 (reference) | 1·05 | 0·73, 1·50 | 1·01 | 0·71, 1·44 | 0·73 | 0·51, 1·04 | 0·04 | |
| Model 3‡ | 1·00 (reference) | 1·06 | 0·74, 1·53 | 1·06 | 0·74, 1·52 | 0·83 | 0·55, 1·24 | 0·37 | |
| Low HDL-cholesterol | Number of cases | 10 | 6 | 18 | 12 | ||||
| Number of cases (per 1000 person) | 47 | 19 | 47 | 27 | |||||
| Model 1* | 1·00 (reference) | 0·40 | 0·14, 1·14 | 1·02 | 0·45, 2·32 | 0·55 | 0·23, 1·33 | 0·54 | |
| Model 2† | 1·00 (reference) | 0·44 | 0·15, 1·27 | 1·04 | 0·44, 2·42 | 0·49 | 0·19, 1·23 | 0·37 | |
| Model 3‡ | 1·00 (reference) | 0·45 | 0·16, 1·30 | 1·11 | 0·46, 2·64 | 0·60 | 0·20, 1·79 | 0·80 | |
| High TAG | Number of cases | 35 | 62 | 83 | 127 | ||||
| Number of cases (per 1000 person) | 164 | 196 | 217 | 287 | |||||
| Model 1* | 1·00 (reference) | 1·26 | 0·79, 2·01 | 1·38 | 0·88, 2·16 | 1·85 | 1·20, 2·85 | 0·003 | |
| Model 2† | 1·00 (reference) | 1·38 | 0·84, 2·25 | 1·47 | 0·92, 2·36 | 1·77 | 1·12, 2·80 | 0·02 | |
| Model 3‡ | 1·00 (reference) | 1·36 | 0·83, 2·22 | 1·41 | 0·87, 2·28 | 1·57 | 0·93, 2·64 | 0·12 | |
| Women | |||||||||
| n | 330 | 226 | 161 | 100 | |||||
| Dyslipidaemia | Number of cases | 140 | 77 | 54 | 31 | ||||
| Number of cases (per 1000 person) | 424 | 341 | 335 | 310 | |||||
| Model 1* | 1·00 (reference) | 0·72 | 0·49, 1·04 | 0·65 | 0·43, 0·99 | 0·64 | 0·39, 1·07 | 0·02 | |
| Model 2† | 1·00 (reference) | 0·64 | 0·44, 0·95 | 0·59 | 0·38, 0·92 | 0·57 | 0·34, 0·98 | 0·007 | |
| Model 3‡ | 1·00 (reference) | 0·64 | 0·44, 0·95 | 0·59 | 0·38, 0·93 | 0·58 | 0·31, 1·07 | 0·01 | |
| High LDL-cholesterol | Number of cases | 130 | 69 | 48 | 26 | ||||
| Number of cases (per 1000 person) | 394 | 305 | 298 | 260 | |||||
| Model 1* | 1·00 (reference) | 0·68 | 0·46, 0·99 | 0·61 | 0·39, 0·94 | 0·57 | 0·34, 0·98 | 0·008 | |
| Model 2† | 1·00 (reference) | 0·62 | 0·42, 0·92 | 0·56 | 0·36, 0·88 | 0·53 | 0·30, 0·91 | 0·003 | |
| Model 3‡ | 1·00 (reference) | 0·62 | 0·42, 0·92 | 0·57 | 0·36, 0·90 | 0·54 | 0·29, 1·03 | 0·007 | |
| Low HDL-cholesterol | Number of cases | 15 | 8 | 7 | 7 | ||||
| Number of cases (per 1000 person) | 45 | 35 | 43 | 70 | |||||
| Model 1* | 1·00 (reference) | 0·74 | 0·30, 1·81 | 0·90 | 0·35, 2·32 | 1·16 | 0·43, 3·11 | 0·85 | |
| Model 2† | 1·00 (reference) | 0·74 | 0·29, 1·87 | 1·00 | 0·38, 2·65 | 1·16 | 0·41, 3·31 | 0·79 | |
| Model 3‡ | 1·00 (reference) | 0·79 | 0·31, 2·00 | 1·22 | 0·45, 3·30 | 2·23 | 0·69, 7·27 | 0·27 | |
| High TAG | Number of cases | 22 | 10 | 7 | 5 | ||||
| Number of cases (per 1000 person) | 67 | 44 | 43 | 50 | |||||
| Model 1* | 1·00 (reference) | 0·67 | 0·30, 1·50 | 0·72 | 0·29, 1·76 | 0·61 | 0·20, 1·81 | 0·29 | |
| Model 2† | 1·00 (reference) | 0·61 | 0·26, 1·46 | 0·76 | 0·29, 1·98 | 0·58 | 0·17, 1·98 | 0·33 | |
| Model 3‡ | 1·00 (reference) | 0·58 | 0·24, 1·40 | 0·63 | 0·23, 1·72 | 0·32 | 0·06, 1·64 | 0·14 | |
HOMA-IR, homoeostasis model assessment of insulin resistance; MVPA, moderate-to-vigorous physical activity.
*
Adjusted for age, sex, marital status, educational status, household income, use of antihypertensive drugs, use of diabetes drugs, smoking status, MVPA, energy intake.
†
Additionally adjusted for waist circumference and HOMA-IR.
‡
Additionally adjusted for alcohol intake (g/d).